undamentalytics Newsletter
Sign in

Nexgel, Inc. (NXGL) stock

Add to watchlist

Add holding +

NASDAQ: NXGL Nasdaq Health Care Supplies Next results ~November 10, 2026

D Fundamentals grade

Nexgel, Inc. is a US-listed company in the health care supplies industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$1.1

Price-to-sales vs peers

Base case. Range ~$1.1–$3.7. Sales per share times peers' typical price-to-sales; used only when earnings are negative.

Price vs value

No Buy/Hold/Sell rating is issued: only 1 valuation models apply; a rating needs 3.

Nexgel, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 1 selling0 purchases and 12 sales by directors and officers, last 12 monthsInsider trades
  • Funds8 adding, 7 cuttingOf 2 active managers that changed their stake, 1 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Nexgel files

Where Nexgel stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $12m, up 3.4% on a year earlier, slower than the 10.1% growth a quarter earlier. Free-cash-flow margin fell to -36.1% from -29.1% a year earlier. Operating margin narrowed to -44.8% from -26.1%. The diluted share count is up 14.5% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 3 of our 7 financial-health checks. Our price-to-sales vs peers value is $1.33 a share, against a share price of $3.98.

Source: 10-Q filed August 17, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 10, 2026 (estimated)

Nexgel, Inc.'s trailing-twelve-month revenue grew 3.4% year on year, with a free-cash-flow margin of -36.1%. Where it stands out: days sales outstanding of 33 days ranks 2 of 11 health care supplies companies we cover. Where it lags: change in share count of 14.5% ranks 12 of 12 health care supplies companies we cover.

Current signal Balance sheet growing far ahead of sales: Total assets grew 172% year over year while revenue grew 3% — the balance sheet is expanding 169 points faster than the business it supports.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Growth slowing. The growth rate is 6.8 points lower than a quarter earlier.
  • Loss-making. Operating margin is -44.8%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 18.7 points on a year ago.
  • Burning cash. Free cash flow was -36.1% of revenue over the last 12 months.
  • Share dilution. Diluted shares rose 14.5% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 128% and a beta of 0.2 against the S&P 500.

Latest results: FY2026 Q2

Filed August 17, 2026
Earnings per share
-$10.32 against an average estimate of -$2.40: missed by 329.8%
Revenue
$4m, up 27.8% on a year earlier
Share reaction
-31.9% in the first session after the results on August 17, 2026, against -1.1% for the S&P 500
Next report
November 10, 2026; average EPS estimate -$4.80

Nexgel's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+8.0%
  • 1 week-4.3%
  • 1 month+8.9%
  • This year-88.2%
  • 1 year-92.3%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$12.1M
Operating margin
-44.8%
Net margin
-51.3%
EPS (TTM, diluted)
$-0.74

Growth

Revenue growth
+3.4%
Change in growth rate
−6.8 pts
Share count change
+14.5%

Cash

Free cash flow (TTM)
-$4.4M
FCF margin
-36.1%
Stock pay % of revenue
5.2%

Earnings

Last results
August 17, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Governance
  2. Announcement
  3. Shareholder vote
  4. Leadership
  5. Results
  6. Shareholder vote
  7. Leadership
  8. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Nexgel, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: only 1 valuation models apply; a rating needs 3.

Valuation models

We value Nexgel, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.3%: the 10-year Treasury yield (4.9%) plus a beta of 0.97 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$1.1 ~$1.5–$3.7 Included, half weight
Combined value Weighted average of the models that apply: the primary model (revenue-to-maturity model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$1.1 ~$1.1–$3.7 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Nexgel, Inc. with Health Care Supplies in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20212022202320242025Now
Share price$52.20$25.00$42.60$89.20$32.20$3.79
Market value$4.4bn$139m$242m$581m$253m$32m
+ Net debt (− = net cash)−$11m$0−$2m−$1m$0$1m
Enterprise value$4.4bn$139m$240m$580m$253m$33m
Multiples
Price / sales n/m68.1x59.1x66.9x22.1x2.6x
Price / earnings ——————
Price / free cash flow ——————
EV / EBITDA ——————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

8 /100

Weak moat

How hard Nexgel's competitive advantage looks for rivals to wear away, judged from 7 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Cash operating profit has been a median -41.1% of total assets over 5 years.

  • Pricing power 0 / 20

    Gross margin has been a median 8.7%, moving by 18.9 percentage points (standard deviation) across 8 years.

  • Durability 10 / 20

    Operating margin has been a median -120.3%; its worst year was -222.4%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 7 years, at a median -129.9% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (12 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 10, 2026, before the open. Analysts expect revenue of $4m and EPS of −$4.80 (range −$4.80 to −$4.80) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$18.80 −125% $16m +38%
Next −$4.40 +77% $24m +54%

Next year's EPS estimate has moved −155.0% in 90 days, across 1 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +683.3% on 90 days ago. In the last 30 days, 0 analysts raised Nexgel, Inc.'s forecast and 1 cut it.

Consensus EPS forecast Nexgel, Inc., last 90 days
−$20.00 −$10.00 $0.00 $10.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$2.40 Current fiscal year, 60 days ago: −$2.40 Current fiscal year, 30 days ago: −$2.40 Current fiscal year, 7 days ago: −$2.40 Current fiscal year, Now: −$18.80 −$18.80 Next fiscal year, 90 days ago: $8.00 Next fiscal year, 60 days ago: $8.00 Next fiscal year, 30 days ago: $8.00 Next fiscal year, 7 days ago: $8.00 Next fiscal year, Now: −$4.40 −$4.40

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$2.40$8.00
60 days ago −$2.40$8.00
30 days ago −$2.40$8.00
7 days ago −$2.40$8.00
Now −$18.80−$4.40

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$2.40 −$10.32 −329.8%
Mar 2026 −$1.40 −$2.20 −57.1%
Dec 2025 −$1.80 −$2.98 −65.3%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

1 analysts, Oct 2026
Buy00%
Hold1100%
Sell00%

Monthly trend

  1. Oct 202611
  2. Sep 202611

Counts of recommendations published by analysts covering Nexgel, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
25.0%
of tradable shares
Days to cover
0.5
at average volume
Short interest, 1 month
+962%
to October 15, 2026
Held by institutions
14%
of shares
Held by insiders
14.0%
of shares
Employees
19
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −92.3%

$49.20 on October 31, 2025 to $3.79

ThenNowEffect
Revenue (last 12 months) $12m $12m +3.4%
P/S multiple 30.7x 2.6x −91.5%
Share count 7m 8m −12.7%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years −90.1%

$38.20 on November 3, 2023 to $3.79

ThenNowEffect
Revenue (last 12 months) $3m $12m +319.1%
P/S multiple 74.3x 2.6x −96.5%
Share count 6m 8m −32.8%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 20222023202420252026 to date
Return
NXGL−52%+70%+109%−64%−88%
Industry peers (median)−45%+22%−13%−13%−7%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
NXGL42%67%67%25%27%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
NXGL−64%−49%−31%−67%−92%
S&P 500−25%−10%−8%−19%−9%

Worst fall since December 22, 2021: 97% from December 16, 2024 to October 8, 2026. Getting back needed a 3187% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$3.00 – $49.60
From 52-week high
−92.4%
vs 50-day average
−25.4%
vs 200-day average
−69.4%
Volatility (1 year)
128%
Beta vs S&P 500
0.21

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 7 down
typical move ±10.3%
After a week
4 up, 8 down
typical move ±12.8%
After a month
4 up, 8 down
typical move ±20.4%
Results releasedNext dayS&P 500 next day5 days21 days
August 17, 2026 −31.9% −1.1% −32.7% −56.1%
November 12, 2025 −16.7% −1.6% −23.7% −26.8%
August 12, 2025 −9.4% +1.4% −9.8% −6.8%
May 13, 2025 −7.8% +0.8% −14.0% −18.7%
March 24, 2025 +12.2% +2.0% +10.4% 0.0%
January 22, 2025 +0.9% +1.1% +6.8% −1.5%
November 14, 2024 −7.0% −1.9% −0.6% +49.8%
October 10, 2024 +20.8% +0.4% +23.3% +35.0%
August 14, 2024 −3.2% +2.0% −5.0% −2.2%
July 8, 2024 +0.9% +0.2% −3.2% +20.4%
May 13, 2024 +0.1% +0.5% +5.1% +4.7%
April 1, 2024 −12.8% −0.8% −18.9% −22.3%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Nexgel, Inc. in five measures

Fundamentals grade D
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Nexgel, Inc.
$0 $5M $10M $15M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $3.5M Revenue (TTM), FY23 Q4: $4.1M Revenue (TTM), FY24 Q1: $4.7M Revenue (TTM), FY24 Q2: $5M Revenue (TTM), FY24 Q3: $6.7M Revenue (TTM), FY24 Q4: $8.7M Revenue (TTM), FY25 Q1: $10.2M Revenue (TTM), FY25 Q2: $11.7M Revenue (TTM), FY25 Q3: $11.7M Revenue (TTM), FY25 Q4: $11.4M Revenue (TTM), FY26 Q1: $11.3M Revenue (TTM), FY26 Q2: $12.1M $12.1M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $3.5M
FY23 Q4 $4.1M
FY24 Q1 $4.7M
FY24 Q2 $5M
FY24 Q3 $6.7M
FY24 Q4 $8.7M
FY25 Q1 $10.2M
FY25 Q2 $11.7M
FY25 Q3 $11.7M
FY25 Q4 $11.4M
FY26 Q1 $11.3M
FY26 Q2 $12.1M
Revenue growth, TTM YoY Nexgel, Inc.
0% 50% 100% 150% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 71.6% Revenue growth, TTM YoY, FY23 Q4: 99.6% Revenue growth, TTM YoY, FY24 Q1: 108.4% Revenue growth, TTM YoY, FY24 Q2: 74.0% Revenue growth, TTM YoY, FY24 Q3: 90.5% Revenue growth, TTM YoY, FY24 Q4: 112.4% Revenue growth, TTM YoY, FY25 Q1: 115.9% Revenue growth, TTM YoY, FY25 Q2: 133.0% Revenue growth, TTM YoY, FY25 Q3: 73.4% Revenue growth, TTM YoY, FY25 Q4: 31.5% Revenue growth, TTM YoY, FY26 Q1: 10.1% Revenue growth, TTM YoY, FY26 Q2: 3.4% 3.4%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 71.6%
FY23 Q4 99.6%
FY24 Q1 108.4%
FY24 Q2 74.0%
FY24 Q3 90.5%
FY24 Q4 112.4%
FY25 Q1 115.9%
FY25 Q2 133.0%
FY25 Q3 73.4%
FY25 Q4 31.5%
FY26 Q1 10.1%
FY26 Q2 3.4%
Operating margin (TTM) Nexgel, Inc.
-100% -50% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -86.0% Operating margin (TTM), FY23 Q4: -85.0% Operating margin (TTM), FY24 Q1: -73.1% Operating margin (TTM), FY24 Q2: -75.0% Operating margin (TTM), FY24 Q3: -58.4% Operating margin (TTM), FY24 Q4: -40.9% Operating margin (TTM), FY25 Q1: -33.8% Operating margin (TTM), FY25 Q2: -26.1% Operating margin (TTM), FY25 Q3: -25.5% Operating margin (TTM), FY25 Q4: -29.4% Operating margin (TTM), FY26 Q1: -31.4% Operating margin (TTM), FY26 Q2: -44.8% -44.8%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -86.0%
FY23 Q4 -85.0%
FY24 Q1 -73.1%
FY24 Q2 -75.0%
FY24 Q3 -58.4%
FY24 Q4 -40.9%
FY25 Q1 -33.8%
FY25 Q2 -26.1%
FY25 Q3 -25.5%
FY25 Q4 -29.4%
FY26 Q1 -31.4%
FY26 Q2 -44.8%
FCF margin (TTM) Nexgel, Inc.
-150% -100% -50% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -110.9% FCF margin (TTM), FY23 Q4: -96.1% FCF margin (TTM), FY24 Q1: -92.5% FCF margin (TTM), FY24 Q2: -78.0% FCF margin (TTM), FY24 Q3: -60.3% FCF margin (TTM), FY24 Q4: -49.6% FCF margin (TTM), FY25 Q1: -35.8% FCF margin (TTM), FY25 Q2: -29.1% FCF margin (TTM), FY25 Q3: -24.8% FCF margin (TTM), FY25 Q4: -15.4% FCF margin (TTM), FY26 Q1: -16.4% FCF margin (TTM), FY26 Q2: -36.1% -36.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -110.9%
FY23 Q4 -96.1%
FY24 Q1 -92.5%
FY24 Q2 -78.0%
FY24 Q3 -60.3%
FY24 Q4 -49.6%
FY25 Q1 -35.8%
FY25 Q2 -29.1%
FY25 Q3 -24.8%
FY25 Q4 -15.4%
FY26 Q1 -16.4%
FY26 Q2 -36.1%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 2 1 1 2 2 4 9 11 12
Gross profit 1 −0 −0 0 0 0 3 5 4
EBITDA −2 −2 −2 −2 −3 −3 −3 −3 −4
Operating income −2 −2 −2 −3 −3 −3 −4 −3 −5
Net income −2 −2 −2 −4 −5 −3 −3 −3 −6
Diluted EPS −$0.01 −$0.00 −$0.04 −$0.05 −$0.85 −$0.56 −$0.50 −$0.38 −$0.74
Growth (year on year)
Revenue — −67.6% −6.0% +130.1% +32.0% +99.7% +112.5% +31.5% +3.4%
Margins
Gross margin 23.2% −19.1% −43.2% 0.5% 12.5% 9.1% 31.6% 39.5% 35.1%
EBITDA margin −70.8% −259.0% −327.9% −158.4% −158.0% −79.5% −35.9% −25.4% −35.2%
Operating margin −85.3% −268.3% −335.3% −165.7% −163.5% −85.0% −40.9% −29.3% −44.8%
Net margin −85.3% −268.2% −335.9% −277.9% −231.7% −77.2% −37.8% −26.3% −51.3%
Free-cash-flow margin — −253.0% −313.5% −194.8% −150.8% −96.2% −49.6% −12.1% −26.6%
Cash flow
Cash from operations −2 −2 −2 −3 −3 −3 −4 −1 −3
Capital spending — 0 0 0 0 1 0 0 0
Free cash flow — −2 −2 −3 −3 −4 −4 −1 −3
Stock-based pay 0 0 0 0 0 0 0 1 1
Free cash flow after stock pay — −2 −2 −3 −3 −4 −5 −2 −4
Balance sheet
Cash 0 0 0 13 — 3 2 — 2
Total debt 0 0 0 2 0 1 1 1 3
Net debt (negative = net cash) 0 −0 0 −11 — −2 −1 — 1
Diluted shares 143m 388m 64m 85m 6m 6m 7m 8m 8m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

3 of 7 checks passed · June 30, 2026
What it owns · $26m
Short-term assets $6mLonger-term assets $20m
What it owes, and who funded it · $26m
Short-term liabilities $14mLonger-term liabilities $7mShareholders' equity $5m
  • Short-term assets cover short-term liabilities $6m of assets due within a year against $14m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $6m short-term assets against $7m of longer-dated liabilities.
  • More cash than debt $2m of cash against $437,000 of debt.
  • Debt below 40% of shareholders' equity Debt is 9% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 2% to 9% over five years.
  • A year's operating cash flow covers at least 20% of debt −$3m of operating cash flow against $437,000 of debt.
  • Operating profit covers interest at least five times over No material interest expense reported.

From Nexgel, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+14.5%
year over year
R&D spending
0.0%
of revenue
Sales & admin spending
79.7%
of revenue
Days sales outstanding
33 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care supplies
Last 12 months unless stated NXGL SINT OSUR MDXG ORGO UFPT Median
Revenue, last 12 months $12m $1m $112m $304m $457m $632m $1.0bn
Revenue growth, last 12 months 3.4% −28.5% −18.9% −22.8% 6.5% 7.3% 3.4%
Revenue growth, 3-year average 61.2% −15.9% −38.4% −0.6% 0.0% 17.8% 0.0%
Revenue growth, latest quarter 27.8% 199.3% −1.9% −45.2% −56.7% 15.1% 0.6%
Gross margin 35.1% 52.9% 42.6% 77.3% 75.9% 28.5% 52.9%
Operating margin −44.8% −884.8% −48.1% −8.3% −7.8% 15.3% 3.3%
Operating margin, 3-year average −48.6% −661.7% −28.5% 8.0% −5.2% 15.4% 2.2%
Net margin −51.3% −848.2% −43.7% −6.3% −18.4% 11.4% 1.4%
Cash from operations / revenue −26.6% −760.8% −38.1% 6.8% 7.0% 11.3% 10.6%
Free-cash-flow margin −36.1% −777.1% −42.8% 2.0% 4.6% 9.0% 6.7%
Free-cash-flow margin, 3-year average −47.7% −520.5% −8.5% 11.2% −1.4% 10.5% 9.8%
Stock pay / revenue 5.2% 153.7% 8.3% 1.6% 3.1% 1.6% 2.5%
Change in share count 14.5% — −4.9% −0.9% 1.7% 0.2% −0.4%

Median of all 13 companies we cover in health care supplies. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

13 health care supplies companies
Measure Company Peer median Rank
Revenue growth Growth 3.4% 3.4% 7 of 13
Change in growth rate Growth -6.8pp -0.3pp 12 of 13
Gross margin Profitability 35.1% 52.9% 12 of 13
Operating margin Profitability -44.8% 3.3% 11 of 13
Net margin Profitability -51.3% 1.4% 12 of 13
Free-cash-flow margin Cash generation -36.1% 6.7% 11 of 13
Stock pay as % of revenue Cash generation 5.2% 2.5% 11 of 13
Long-term debt as % of assets Balance sheet 1.7% 15.4% 2 of 9
Change in share count Balance sheet 14.5% 0.1% 12 of 12
Days sales outstanding Balance sheet 33 days 65 days 2 of 11

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$292,957
Institutions reporting
18
Shares held vs prior quarter
▲ 16.0%
Positions opened / closed
6 / 5

Top buyers and sellers, Q2 2026: 8 institutions bought and 7 sold ; the biggest buyer was Susquehanna International Group, LLP (+85K shares) and the biggest seller Geode Capital Management, LLC (−57K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Susquehanna International Group, LLP $42,655 85K 14.6% New
Virtu Financial LLC $40,000 79K 13.7% New
Geode Capital Management, LLC $36,012 72K 12.3% ▼ 44.1%
HRT Financial LP $34,000 69K 11.6% ▲ 348.4%
Morgan Stanley $27,545 55K 9.4% 0.0%
Vanguard Capital Management LLC $24,509 49K 8.4% 0.0%
Citadel Advisors LLC $20,529 41K 7.0% New
Vanguard Fiduciary Trust Co $17,054 34K 5.8% 0.0%
UBS Group AG $12,392 25K 4.2% ▲ 272.9%
Jane Street Group, LLC $10,324 21K 3.5% ▼ 51.1%
State Street Corp $8,647 17K 3.0% 0.0%
Northern Trust Corp $6,729 13K 2.3% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Nexgel, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $46,810 12 trades by 1 insider · 22% under pre-set plans
Net ▼ $46,810 net selling
Insider Date Trade Shares Price Value
Levy Adam R. Chief Executive Officer June 23, 2026 Sell 5,000 $0.59 $2,950
Levy Adam R. Chief Executive Officer June 18, 2026 Sell 6,000 $0.59 $3,540
Levy Adam R. Chief Executive Officer June 11, 2026 Sell 3,000 $0.61 $1,830
Levy Adam R. Chief Executive Officer June 8, 2026 Sell 3,000 $0.55 $1,650
Levy Adam R. Chief Executive Officer June 4, 2026 Sell 3,000 $0.59 $1,770
Levy Adam R. Chief Executive Officer June 1, 2026 Sell 2,000 $0.59 $1,180
Levy Adam R. Chief Executive Officer May 29, 2026 Sell 3,000 $0.60 $1,800
Levy Adam R. Chief Executive Officer May 28, 2026 Sell 7,000 $0.61 $4,270
Levy Adam R. Chief Executive Officer May 27, 2026 Sell 3,000 $0.60 $1,800
Levy Adam R. Chief Executive Officer December 24, 2025 Sell 4,000 $1.57 $6,280
Levy Adam R. Chief Executive Officer December 22, 2025 Sell 6,000 $1.61 $9,660
Levy Adam R. Chief Executive Officer November 6, 2025 Sell pre-set plan 4,000 $2.52 $10,080

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • August 17, 2026
  • November 12, 2025
  • August 12, 2025
  • May 13, 2025
  • March 24, 2025
  • January 22, 2025

Recent SEC filings

Data status

When each part of this page on Nexgel, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Nexgel, Inc. in brief

What does Nexgel, Inc. do?
Nexgel, Inc. is a US-listed company in the health care supplies industry. Its financial year ends in December.
What is Nexgel, Inc.'s stock ticker?
Nexgel, Inc. trades under the ticker NXGL on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Nexgel, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Nexgel, Inc. reported revenue of $12.1M, 3.4% higher than a year earlier, according to its SEC filings.
What is Nexgel, Inc.'s free cash flow?
Nexgel, Inc.'s free-cash-flow margin is -36.1% of revenue over the trailing twelve months, ranking 11 of the 13 health care supplies companies we cover.
Who are Nexgel, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Susquehanna International Group, LLP, Virtu Financial LLC and Geode Capital Management, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Nexgel, Inc.'s market cap?
On November 2, 2026, Nexgel, Inc.'s market capitalisation was about $31.6M and net debt of $1.4M. Market figures come from third-party market data and may be delayed.
How much debt does Nexgel, Inc. have?
Nexgel, Inc.'s debt-to-equity ratio is 8.8%, from its latest balance sheet (2.2% five years earlier). The financial health section below sets out its other solvency checks.
Who are Nexgel, Inc.'s competitors?
In our Health Care Supplies peer group, the companies closest to Nexgel, Inc. are Sintx Technologies, Inc., Orasure Technologies Inc, Mimedx Group, Inc., Organogenesis Holdings Inc. and UFP Technologies Inc. The side-by-side comparison below sets their revenue, margins and growth against Nexgel, Inc.'s.
Are insiders buying or selling Nexgel, Inc. stock?
Over the last 12 months, Nexgel, Inc.'s directors and officers reported 0 open-market purchases and 12 sales on Form 4. The insider trading page charts every trade.
When is Nexgel, Inc.'s next earnings date?
Around November 10, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Nexgel, Inc. announces its own schedule.